Effect  ||| S:0 E:7 ||| NN
on  ||| S:7 E:10 ||| IN
outcomes  ||| S:10 E:19 ||| NNS
and  ||| S:19 E:23 ||| CC
exercise  ||| S:23 E:32 ||| NN
performance  ||| S:32 E:44 ||| NN
of  ||| S:44 E:47 ||| IN
anemia  ||| S:47 E:54 ||| NN
in  ||| S:54 E:57 ||| IN
patients  ||| S:57 E:66 ||| NNS
with  ||| S:66 E:71 ||| IN
aortic  ||| S:71 E:78 ||| JJ
stenosis  ||| S:78 E:87 ||| NNS
who  ||| S:87 E:91 ||| WP
underwent  ||| S:91 E:101 ||| VBD
transcatheter  ||| S:101 E:115 ||| JJ
aortic  ||| S:115 E:122 ||| JJ
valve  ||| S:122 E:128 ||| JJ
replacement  ||| S:128 E:140 ||| NN
The  ||| S:140 E:144 ||| DT
objectives  ||| S:144 E:155 ||| NNS
of  ||| S:155 E:158 ||| IN
this  ||| S:158 E:163 ||| DT
study  ||| S:163 E:169 ||| NN
were  ||| S:169 E:174 ||| VBD
to  ||| S:174 E:177 ||| TO
determine  ||| S:177 E:187 ||| VB
the  ||| S:187 E:191 ||| DT
causes  ||| S:191 E:198 ||| NNS
and  ||| S:198 E:202 ||| CC
impact  ||| S:202 E:209 ||| NN
of  ||| S:209 E:212 ||| IN
anemia  ||| S:212 E:219 ||| NN
and  ||| S:219 E:223 ||| CC
hemoglobin  ||| S:223 E:234 ||| JJ
level  ||| S:234 E:240 ||| NN
on  ||| S:240 E:243 ||| IN
functional  ||| S:243 E:254 ||| JJ
status ||| S:254 E:260 ||| NN
,  ||| S:260 E:262 ||| ,
physical  ||| S:262 E:271 ||| JJ
performance ||| S:271 E:282 ||| NN
,  ||| S:282 E:284 ||| ,
and  ||| S:284 E:288 ||| CC
quality  ||| S:288 E:296 ||| NN
of  ||| S:296 E:299 ||| IN
life  ||| S:299 E:304 ||| NN
in  ||| S:304 E:307 ||| IN
the  ||| S:307 E:311 ||| DT
preprocedural  ||| S:311 E:325 ||| JJ
evaluation  ||| S:325 E:336 ||| NN
and  ||| S:336 E:340 ||| CC
follow-up  ||| S:340 E:350 ||| JJ
of  ||| S:350 E:353 ||| IN
transcatheter  ||| S:353 E:367 ||| FW
aortic  ||| S:367 E:374 ||| FW
valve  ||| S:374 E:380 ||| FW
replacement  ||| S:380 E:392 ||| FW
( ||| S:392 E:393 ||| -LRB-
TAVR ||| S:393 E:397 ||| NNP
)  ||| S:397 E:399 ||| -RRB-
candidates ||| S:399 E:409 ||| NNS
.  ||| S:409 E:411 ||| .
A  ||| S:411 E:413 ||| DT
total  ||| S:413 E:419 ||| NN
of  ||| S:419 E:422 ||| IN
438  ||| S:422 E:426 ||| CD
patients  ||| S:426 E:435 ||| NNS
who  ||| S:435 E:439 ||| WP
underwent  ||| S:439 E:449 ||| VBD
TAVR  ||| S:449 E:454 ||| NNP
were  ||| S:454 E:459 ||| VBD
included ||| S:459 E:467 ||| VBN
.  ||| S:467 E:469 ||| .
Anemia  ||| S:469 E:476 ||| NNP
was  ||| S:476 E:480 ||| VBD
defined  ||| S:480 E:488 ||| VBN
as  ||| S:488 E:491 ||| IN
a  ||| S:491 E:493 ||| DT
hemoglobin  ||| S:493 E:504 ||| NN
level  ||| S:504 E:510 ||| NN
< ||| S:510 E:511 ||| SYM
12 g ||| S:511 E:515 ||| CD
/ ||| S:515 E:516 ||| CD
dl  ||| S:516 E:519 ||| NN
in  ||| S:519 E:522 ||| IN
women  ||| S:522 E:528 ||| NNS
and  ||| S:528 E:532 ||| CC
< ||| S:532 E:533 ||| SYM
13 g ||| S:533 E:537 ||| CD
/ ||| S:537 E:538 ||| CD
dl  ||| S:538 E:541 ||| NN
in  ||| S:541 E:544 ||| IN
men ||| S:544 E:547 ||| NNS
.  ||| S:547 E:549 ||| .
Before  ||| S:549 E:556 ||| IN
TAVR ||| S:556 E:560 ||| NNP
,  ||| S:560 E:562 ||| ,
anemia  ||| S:562 E:569 ||| NN
was  ||| S:569 E:573 ||| VBD
encountered  ||| S:573 E:585 ||| VBN
in  ||| S:585 E:588 ||| IN
282  ||| S:588 E:592 ||| CD
patients  ||| S:592 E:601 ||| NNS
( ||| S:601 E:602 ||| -LRB-
64.4 ||| S:602 E:606 ||| NNP
% ||| S:606 E:607 ||| NN
) ||| S:607 E:608 ||| -RRB-
.  ||| S:608 E:610 ||| .
A  ||| S:610 E:612 ||| DT
potential  ||| S:612 E:622 ||| JJ
treatable  ||| S:622 E:632 ||| JJ
cause  ||| S:632 E:638 ||| NN
of  ||| S:638 E:641 ||| IN
anemia  ||| S:641 E:648 ||| NN
was  ||| S:648 E:652 ||| VBD
detected  ||| S:652 E:661 ||| VBN
in  ||| S:661 E:664 ||| IN
90.4 ||| S:664 E:668 ||| CD
%  ||| S:668 E:670 ||| NN
of  ||| S:670 E:673 ||| IN
patients  ||| S:673 E:682 ||| NNS
and  ||| S:682 E:686 ||| CC
was  ||| S:686 E:690 ||| VBD
attributed  ||| S:690 E:701 ||| VBN
to  ||| S:701 E:704 ||| TO
iron  ||| S:704 E:709 ||| VB
deficiency  ||| S:709 E:720 ||| NN
in  ||| S:720 E:723 ||| IN
53 ||| S:723 E:725 ||| CD
%  ||| S:725 E:727 ||| NN
of  ||| S:727 E:730 ||| IN
them ||| S:730 E:734 ||| PRP
.  ||| S:734 E:736 ||| .
The  ||| S:736 E:740 ||| DT
occurrence  ||| S:740 E:751 ||| NN
of  ||| S:751 E:754 ||| IN
anemia  ||| S:754 E:761 ||| NN
was  ||| S:761 E:765 ||| VBD
an  ||| S:765 E:768 ||| DT
independent  ||| S:768 E:780 ||| JJ
predictor  ||| S:780 E:790 ||| NN
of  ||| S:790 E:793 ||| IN
poorer  ||| S:793 E:800 ||| JJR
performance  ||| S:800 E:812 ||| NN
in  ||| S:812 E:815 ||| IN
the  ||| S:815 E:819 ||| DT
6-minute  ||| S:819 E:828 ||| JJ
walk  ||| S:828 E:833 ||| NN
test  ||| S:833 E:838 ||| NN
( ||| S:838 E:839 ||| -LRB-
6MWT ||| S:839 E:843 ||| NNP
) ||| S:843 E:844 ||| -RRB-
,  ||| S:844 E:846 ||| ,
a  ||| S:846 E:848 ||| DT
lower  ||| S:848 E:854 ||| JJR
Duke  ||| S:854 E:859 ||| NNP
Activity  ||| S:859 E:868 ||| NNP
Status  ||| S:868 E:875 ||| NNP
Index  ||| S:875 E:881 ||| NNP
score ||| S:881 E:886 ||| NN
,  ||| S:886 E:888 ||| ,
and  ||| S:888 E:892 ||| CC
Kansas  ||| S:892 E:899 ||| NNP
City  ||| S:899 E:904 ||| NNP
Cardiomyopathy  ||| S:904 E:919 ||| NNP
Questionnaires  ||| S:919 E:934 ||| NNP
overall ||| S:934 E:941 ||| JJ
,  ||| S:941 E:943 ||| ,
clinical ||| S:943 E:951 ||| JJ
,  ||| S:951 E:953 ||| ,
and  ||| S:953 E:957 ||| CC
social  ||| S:957 E:964 ||| JJ
limitation  ||| S:964 E:975 ||| NN
scores  ||| S:975 E:982 ||| NNS
( ||| S:982 E:983 ||| -LRB-
p  ||| S:983 E:985 ||| CD
< ||| S:985 E:986 ||| SYM
0.05  ||| S:986 E:991 ||| CD
for  ||| S:991 E:995 ||| IN
all ||| S:995 E:998 ||| DT
) ||| S:998 E:999 ||| -RRB-
.  ||| S:999 E:1001 ||| .
A  ||| S:1001 E:1003 ||| DT
lower  ||| S:1003 E:1009 ||| JJR
hemoglobin  ||| S:1009 E:1020 ||| NN
level  ||| S:1020 E:1026 ||| NN
was  ||| S:1026 E:1030 ||| VBD
associated  ||| S:1030 E:1041 ||| VBN
with  ||| S:1041 E:1046 ||| IN
a  ||| S:1046 E:1048 ||| DT
higher  ||| S:1048 E:1055 ||| JJR
prevalence  ||| S:1055 E:1066 ||| NN
of  ||| S:1066 E:1069 ||| IN
New  ||| S:1069 E:1073 ||| NNP
York  ||| S:1073 E:1078 ||| NNP
Heart  ||| S:1078 E:1084 ||| NNP
Association  ||| S:1084 E:1096 ||| NNP
class  ||| S:1096 E:1102 ||| NN
III  ||| S:1102 E:1106 ||| NNP
to  ||| S:1106 E:1109 ||| TO
IV  ||| S:1109 E:1112 ||| NNP
( ||| S:1112 E:1113 ||| -LRB-
p  ||| S:1113 E:1115 ||| FW
< ||| S:1115 E:1116 ||| SYM
0.001 ||| S:1116 E:1121 ||| FW
)  ||| S:1121 E:1123 ||| -RRB-
and  ||| S:1123 E:1127 ||| CC
correlated  ||| S:1127 E:1138 ||| JJ
negatively  ||| S:1138 E:1149 ||| NN
with  ||| S:1149 E:1154 ||| IN
the  ||| S:1154 E:1158 ||| DT
results  ||| S:1158 E:1166 ||| NNS
of  ||| S:1166 E:1169 ||| IN
all  ||| S:1169 E:1173 ||| DT
functional  ||| S:1173 E:1184 ||| JJ
tests  ||| S:1184 E:1190 ||| NNS
( ||| S:1190 E:1191 ||| -LRB-
p  ||| S:1191 E:1193 ||| CD
< ||| S:1193 E:1194 ||| SYM
0.02  ||| S:1194 E:1199 ||| CD
for  ||| S:1199 E:1203 ||| IN
all ||| S:1203 E:1206 ||| DT
) ||| S:1206 E:1207 ||| -RRB-
.  ||| S:1207 E:1209 ||| .
At  ||| S:1209 E:1212 ||| IN
follow-up ||| S:1212 E:1221 ||| NNP
,  ||| S:1221 E:1223 ||| ,
anemia  ||| S:1223 E:1230 ||| NN
was  ||| S:1230 E:1234 ||| VBD
found  ||| S:1234 E:1240 ||| VBN
in  ||| S:1240 E:1243 ||| IN
62 ||| S:1243 E:1245 ||| CD
%  ||| S:1245 E:1247 ||| NN
of  ||| S:1247 E:1250 ||| IN
patients  ||| S:1250 E:1259 ||| NNS
and  ||| S:1259 E:1263 ||| CC
was  ||| S:1263 E:1267 ||| VBD
associated  ||| S:1267 E:1278 ||| VBN
with  ||| S:1278 E:1283 ||| IN
poorer  ||| S:1283 E:1290 ||| JJR
performance  ||| S:1290 E:1302 ||| NN
in  ||| S:1302 E:1305 ||| IN
the  ||| S:1305 E:1309 ||| DT
6MWT  ||| S:1309 E:1314 ||| NNP
( ||| S:1314 E:1315 ||| -LRB-
p =  ||| S:1315 E:1319 ||| NNP
0.023 ||| S:1319 E:1324 ||| NNP
) ||| S:1324 E:1325 ||| -RRB-
.  ||| S:1325 E:1327 ||| .
A  ||| S:1327 E:1329 ||| DT
lower  ||| S:1329 E:1335 ||| JJR
hemoglobin  ||| S:1335 E:1346 ||| NN
level  ||| S:1346 E:1352 ||| NN
after  ||| S:1352 E:1358 ||| IN
TAVR  ||| S:1358 E:1363 ||| NNP
was  ||| S:1363 E:1367 ||| VBD
a  ||| S:1367 E:1369 ||| DT
predictor  ||| S:1369 E:1379 ||| NN
of  ||| S:1379 E:1382 ||| IN
poorer  ||| S:1382 E:1389 ||| JJR
New  ||| S:1389 E:1393 ||| NNP
York  ||| S:1393 E:1398 ||| NNP
Heart  ||| S:1398 E:1404 ||| NNP
Association  ||| S:1404 E:1416 ||| NNP
class  ||| S:1416 E:1422 ||| NN
( ||| S:1422 E:1423 ||| -LRB-
p =  ||| S:1423 E:1427 ||| NNP
0.020 ||| S:1427 E:1432 ||| NNP
)  ||| S:1432 E:1434 ||| -RRB-
and  ||| S:1434 E:1438 ||| CC
correlated  ||| S:1438 E:1449 ||| JJ
negatively  ||| S:1449 E:1460 ||| NN
with  ||| S:1460 E:1465 ||| IN
the  ||| S:1465 E:1469 ||| DT
distance  ||| S:1469 E:1478 ||| NN
walked  ||| S:1478 E:1485 ||| VBD
in  ||| S:1485 E:1488 ||| IN
the  ||| S:1488 E:1492 ||| DT
6MWT  ||| S:1492 E:1497 ||| NNP
( ||| S:1497 E:1498 ||| -LRB-
r = -0.191 ||| S:1498 E:1508 ||| NNP
,  ||| S:1508 E:1510 ||| ,
p =  ||| S:1510 E:1514 ||| CD
0.004 ||| S:1514 E:1519 ||| CD
)  ||| S:1519 E:1521 ||| -RRB-
and  ||| S:1521 E:1525 ||| CC
Duke  ||| S:1525 E:1530 ||| NNP
Activity  ||| S:1530 E:1539 ||| NNP
Status  ||| S:1539 E:1546 ||| NNP
Index  ||| S:1546 E:1552 ||| NNP
score  ||| S:1552 E:1558 ||| NN
( ||| S:1558 E:1559 ||| -LRB-
r = -0.158 ||| S:1559 E:1569 ||| NNP
,  ||| S:1569 E:1571 ||| ,
p =  ||| S:1571 E:1575 ||| CD
0.011 ||| S:1575 E:1580 ||| CD
)  ||| S:1580 E:1582 ||| -RRB-
at  ||| S:1582 E:1585 ||| IN
6-month  ||| S:1585 E:1593 ||| NNP
follow-up ||| S:1593 E:1602 ||| NNP
.  ||| S:1602 E:1604 ||| .
In  ||| S:1604 E:1607 ||| IN
conclusion ||| S:1607 E:1617 ||| NN
,  ||| S:1617 E:1619 ||| ,
anemia  ||| S:1619 E:1626 ||| NN
was  ||| S:1626 E:1630 ||| VBD
very  ||| S:1630 E:1635 ||| RB
common  ||| S:1635 E:1642 ||| JJ
in  ||| S:1642 E:1645 ||| IN
TAVR  ||| S:1645 E:1650 ||| NNP
candidates  ||| S:1650 E:1661 ||| NNS
and  ||| S:1661 E:1665 ||| CC
was  ||| S:1665 E:1669 ||| VBD
attributed  ||| S:1669 E:1680 ||| VBN
to  ||| S:1680 E:1683 ||| TO
iron  ||| S:1683 E:1688 ||| VB
deficiency  ||| S:1688 E:1699 ||| NN
in  ||| S:1699 E:1702 ||| IN
more  ||| S:1702 E:1707 ||| JJR
than  ||| S:1707 E:1712 ||| IN
half  ||| S:1712 E:1717 ||| NN
of  ||| S:1717 E:1720 ||| IN
them ||| S:1720 E:1724 ||| PRP
.  ||| S:1724 E:1726 ||| .
The  ||| S:1726 E:1730 ||| DT
presence  ||| S:1730 E:1739 ||| NN
of  ||| S:1739 E:1742 ||| IN
anemia  ||| S:1742 E:1749 ||| NN
and  ||| S:1749 E:1753 ||| CC
lower  ||| S:1753 E:1759 ||| JJR
hemoglobin  ||| S:1759 E:1770 ||| NN
levels  ||| S:1770 E:1777 ||| NNS
determined  ||| S:1777 E:1788 ||| VBD
poorer  ||| S:1788 E:1795 ||| JJR
functional  ||| S:1795 E:1806 ||| JJ
status  ||| S:1806 E:1813 ||| NN
before  ||| S:1813 E:1820 ||| IN
and  ||| S:1820 E:1824 ||| CC
after  ||| S:1824 E:1830 ||| IN
the  ||| S:1830 E:1834 ||| DT
TAVR  ||| S:1834 E:1839 ||| NNP
procedure ||| S:1839 E:1848 ||| NN
.  ||| S:1848 E:1850 ||| .
These  ||| S:1850 E:1856 ||| DT
results  ||| S:1856 E:1864 ||| NNS
highlight  ||| S:1864 E:1874 ||| VB
the  ||| S:1874 E:1878 ||| DT
importance  ||| S:1878 E:1889 ||| NN
of  ||| S:1889 E:1892 ||| IN
implementing  ||| S:1892 E:1905 ||| VBG
appropriate  ||| S:1905 E:1917 ||| JJ
measures  ||| S:1917 E:1926 ||| NNS
for  ||| S:1926 E:1930 ||| IN
the  ||| S:1930 E:1934 ||| DT
diagnosis  ||| S:1934 E:1944 ||| NN
and  ||| S:1944 E:1948 ||| CC
treatment  ||| S:1948 E:1958 ||| NN
of  ||| S:1958 E:1961 ||| IN
this  ||| S:1961 E:1966 ||| DT
frequent  ||| S:1966 E:1975 ||| JJ
co-morbidity  ||| S:1975 E:1988 ||| JJ
to  ||| S:1988 E:1991 ||| TO
improve  ||| S:1991 E:1999 ||| VB
both  ||| S:1999 E:2004 ||| PDT
the  ||| S:2004 E:2008 ||| DT
accuracy  ||| S:2008 E:2017 ||| NN
of  ||| S:2017 E:2020 ||| IN
preprocedural  ||| S:2020 E:2034 ||| JJ
evaluation  ||| S:2034 E:2045 ||| NN
and  ||| S:2045 E:2049 ||| CC
outcomes  ||| S:2049 E:2058 ||| NNS
of  ||| S:2058 E:2061 ||| IN
TAVR  ||| S:2061 E:2066 ||| NNP
candidates ||| S:2066 E:2076 ||| NNS
.  ||| S:2076 E:2078 ||| .
